Quantifying the gender gap in the HIV care cascade in southern Mozambique: We are missing the men.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      HIV Infections*/diagnosis ; HIV Infections*/epidemiology ; Sex Distribution*; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Mozambique/epidemiology ; Prevalence ; Prospective Studies ; Rural Population ; Young Adult
    • Abstract:
      Background: HIV-infected men have higher rates of delayed diagnosis, reduced antiretroviral treatment (ART) retention and mortality than women. We aimed to assess, by gender, the first two UNAIDS 90 targets in rural southern Mozambique.
      Methods: This analysis was embedded in a larger prospective cohort enrolling individuals with new HIV diagnosis between May 2014-June 2015 from clinic and home-based testing (HBT). We assessed gender differences between steps of the HIV-cascade. Adjusted HIV-community prevalence was estimated using multiple imputation (MI).
      Results: Among 11,773 adults randomized in HBT (7084 female and 4689 male), the response rate before HIV testing was 48.7% among eligible men and 62.0% among women (p<0.001). MI did not significantly modify all-age HIV-prevalence for men but did decrease prevalence estimates in women from 36.4%to 33.0%. Estimated proportion of HIV-infected individuals aware of their status was 75.9% for men and 88.9% for women. In individuals <25 years, we observed up to 22.2% disparity in awareness of serostatus between genders. Among individuals eligible for ART, similar proportions of men and women initiated treatment (81.2% and 85.9%, respectively). Fourfold more men than womenwere in WHO stage III/IV AIDS at first clinical visit. Once on ART, men had a twofold higher 18-month loss to follow-up rate than women.
      Conclusion: The contribution of missing HIV-serostatus data differentially impacted indicators of HIV prevalence and of achievement of UNAIDS targets by age and gender and men were missing long before the second 90. Increased efforts to characterize missing men and their needs will and their needs will allow us to urgently address the barriers to men accessing care and ensure men are not left behind in the UNAIDS 90-90-90 targets achievement.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      PLoS Med. 2011 Oct;8(10):e1001111. (PMID: 22039357)
      J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25526. (PMID: 32589325)
      J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):527-535. (PMID: 29771786)
      Lancet Glob Health. 2020 Feb;8(2):e276-e287. (PMID: 31981557)
      J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):467-473. (PMID: 30148731)
      J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):135-9. (PMID: 19504725)
      AIDS. 2008 Jan 2;22(1):139-44. (PMID: 18090402)
      Clin Infect Dis. 2014 Feb;58(3):432-41. (PMID: 24198226)
      AIDS. 2014 Nov;28 Suppl 4:S533-42. (PMID: 25406756)
      J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):91-9. (PMID: 27082505)
      J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25514. (PMID: 32589337)
      J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25515. (PMID: 32589354)
      Int J Epidemiol. 2013 Oct;42(5):1309-18. (PMID: 24159076)
      J Int AIDS Soc. 2016 Nov 08;19(1):21106. (PMID: 27834182)
      BMC Med Res Methodol. 2014 May 24;14:71. (PMID: 24884457)
      Trop Med Int Health. 2018 Feb;23(2):206-220. (PMID: 29160949)
      PLoS One. 2014 Aug 13;9(8):e104961. (PMID: 25119665)
      J Int AIDS Soc. 2017 Sep 25;20(1):21902. (PMID: 28953328)
      PLoS One. 2012;7(5):e37125. (PMID: 22615917)
      Nature. 2015 Dec 3;528(7580):S77-85. (PMID: 26633769)
      Pac AIDS Alert Bull. 1999;(18):15-6. (PMID: 12349391)
      HIV Med. 2012 Nov;13(10):581-8. (PMID: 22500780)
      PLoS One. 2018 Aug 10;13(8):e0197904. (PMID: 30096139)
      PLoS Med. 2017 Apr 11;14(4):e1002262. (PMID: 28399122)
      PLoS Med. 2015 Nov 24;12(11):e1001905; discussion e1001905. (PMID: 26599699)
      J Int AIDS Soc. 2013 Jun 10;16:18490. (PMID: 23755857)
      J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):411-418. (PMID: 27243903)
      Sex Transm Infect. 2012 Dec;88 Suppl 2:i17-23. (PMID: 23172342)
      Lancet HIV. 2017 Nov;4(11):e505-e513. (PMID: 28779855)
      AIDS. 2009 Mar 13;23(5):621-9. (PMID: 19182677)
      PLoS One. 2018 Dec 21;13(12):e0209586. (PMID: 30576388)
    • Grant Information:
      United States PEPFAR PEPFAR
    • Publication Date:
      Date Created: 20210212 Date Completed: 20210721 Latest Revision: 20240330
    • Publication Date:
      20240330
    • Accession Number:
      PMC7880488
    • Accession Number:
      10.1371/journal.pone.0245461
    • Accession Number:
      33577559